TY - JOUR
T1 - Predictive Value of Cytokines and Immune Activation Biomarkers in AIDS-Related Non-Hodgkin Lymphoma Treated with Rituximab plus Infusional EPOCH (AMC-034 trial)
AU - Epeldegui, Marta
AU - Lee, Jeannette Y.
AU - Martínez, Anna C.
AU - Widney, Daniel P.
AU - Magpantay, Larry I.
AU - Regidor, Deborah
AU - Mitsuyasu, Ronald
AU - Sparano, Joseph A.
AU - Ambinder, Richard F.
AU - Martínez-Maza, Otoniel
N1 - Publisher Copyright:
© 2015 American Association for Cancer Research.
PY - 2016/1/15
Y1 - 2016/1/15
N2 - Purpose: The aims of this study were to determine whether pretreatment plasma levels of cytokines and immune activation- associated molecules changed following treatment for AIDS-NHL with rituximab plus infusional EPOCH, and to determine whether pretreatment levels of these molecules were associated with response to treatment and/or survival. Experimental Design: We quantified plasma levels of B-cell activation-associated molecules (sCD27, sCD30, and sCD23) and cytokines (IL6, IL10, and CXCL13) before and after the initiation of treatment in persons with AIDS-NHL (n = 69) in the AIDS Malignancies Consortium (AMC) 034 study, which evaluated treatment of AIDS-NHL with EPOCH chemotherapy and rituximab. Results: Treatment resulted in decreased plasma levels of some of these molecules (CXCL13, sCD27, and sCD30), with decreased levels persisting for one year following the completion of treatment. Lower levels of CXCL13 before treatment were associated with complete responses following lymphoma therapy. Elevated levels of IL6 pretreatment were associated with decreased overall survival, whereas higher IL10 levels were associated with shorter progression-free survival (PFS), in multivariate analyses. Furthermore, patients with CXCL13 or IL6 levels higher than the median levels for theNHLgroup, as well as those whohad detectable IL10, had lower overall survival and PFS, in Kaplan-Meier analyses. Conclusions: These results indicate that CXCL13, IL6, and IL10 have significant potential as prognostic biomarkers for AIDS-NHL.
AB - Purpose: The aims of this study were to determine whether pretreatment plasma levels of cytokines and immune activation- associated molecules changed following treatment for AIDS-NHL with rituximab plus infusional EPOCH, and to determine whether pretreatment levels of these molecules were associated with response to treatment and/or survival. Experimental Design: We quantified plasma levels of B-cell activation-associated molecules (sCD27, sCD30, and sCD23) and cytokines (IL6, IL10, and CXCL13) before and after the initiation of treatment in persons with AIDS-NHL (n = 69) in the AIDS Malignancies Consortium (AMC) 034 study, which evaluated treatment of AIDS-NHL with EPOCH chemotherapy and rituximab. Results: Treatment resulted in decreased plasma levels of some of these molecules (CXCL13, sCD27, and sCD30), with decreased levels persisting for one year following the completion of treatment. Lower levels of CXCL13 before treatment were associated with complete responses following lymphoma therapy. Elevated levels of IL6 pretreatment were associated with decreased overall survival, whereas higher IL10 levels were associated with shorter progression-free survival (PFS), in multivariate analyses. Furthermore, patients with CXCL13 or IL6 levels higher than the median levels for theNHLgroup, as well as those whohad detectable IL10, had lower overall survival and PFS, in Kaplan-Meier analyses. Conclusions: These results indicate that CXCL13, IL6, and IL10 have significant potential as prognostic biomarkers for AIDS-NHL.
UR - http://www.scopus.com/inward/record.url?scp=84958968962&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84958968962&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-14-0466
DO - 10.1158/1078-0432.CCR-14-0466
M3 - Article
C2 - 26384320
AN - SCOPUS:84958968962
SN - 1078-0432
VL - 22
SP - 328
EP - 336
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 2
ER -
